Premium
Buspirone pharmacokinetics in patients with cirrhosis.
Author(s) -
Dalhoff K,
Poulsen HE,
Garred P,
Placchi M,
Gammans RE,
Mayol RF,
Pfeffer M
Publication year - 1987
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1987.tb03210.x
Subject(s) - buspirone , pharmacokinetics , cmax , cirrhosis , medicine , geometric mean , liver disease , chemistry , gastroenterology , pharmacology , mathematics , agonist , statistics , receptor
The pharmacokinetics of a single oral dose of buspirone (20 mg) were determined in 12 patients with cirrhosis and 12 normal subjects. The mean AUC of buspirone was 55 +/‐ 38 s.d. ng ml‐1 h in cirrhotics and 3.5 +/‐ 2.4 s.d. ng ml‐1 h in normals. The time until maximum concentration (tmax) attained was similar in the two groups (0.6 vs 0.7 h), but mean maximum concentration Cmax was higher in patients (18.8 +/‐ 16.3 s.d. ng ml‐1) than in normals (1.2 +/‐ 0.8 s.d. ng ml‐1). Mean elimination half‐life of buspirone was greater in cirrhotics, but this difference was marginally significant statistically (cirrhotics, 6.1 +/‐ 3.5 s.d. h, normals 3.2 +/‐ 1.5 s.d. h, P = 0.05). Eight of 12 patients and seven of 12 normal subjects had a second peak in the plasma concentrations of buspirone. In patients this occurred at 10.8 +/‐ 7.4 s.d. h after the dose, and its mean concentration was 3.1 +/‐ 6.6 ng ml‐ 1. In normal subjects the second peak occurred at 4.3 +/‐ 2.1 h after the dose and its mean concentration was 0.5 +/‐ 0.3 ng ml‐1. On the kinetic evidence buspirone should be used with caution in liver disease.